Abbonarsi

Cardiogenic shock complicating non-ST-segment elevation myocardial infarction: An 18-year study - 31/12/21

Doi : 10.1016/j.ahj.2021.11.002 
Saraschandra Vallabhajosyula, MD, MSc a, , Huzefa M. Bhopalwala, MBBS b, Pranathi R. Sundaragiri, MD c, Nakeya Dewaswala, MD d, Wisit Cheungpasitporn, MD e, Rajkumar Doshi, MD, MPH f, Abhiram Prasad, MD g, Gurpreet S. Sandhu, MD, PhD g, Allan S. Jaffe, MD g, Malcolm R. Bell, MD g, David R. Holmes, MD g
a Section of Cardiovascular Medicine, Department of Medicine, Wake Forest University School of Medicine, Winston-Salem, NC 
b Department of Medicine, Appalachian Regional Healthcare, Whitesburg, KY 
c Department of Primary Care Internal Medicine, Wake Forest Baptist Health, High Point, NC 
d Division of Cardiovascular Medicine, Department of Medicine, University of Kentucky College of Medicine, Lexington, KY 
e Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 
f Division of Cardiovascular Medicine, Department of Medicine, Saint Joseph University Medical Center, Paterson, NJ 
g Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 

Reprint requests: Saraschandra Vallabhajosyula, MD, MSc, Section of Cardiovascular Medicine, Department of Medicine, Wake Forest University School of Medicine, 306 Westwood Avenue, Suite 401, High Point, NC 27262.Section of Cardiovascular MedicineDepartment of MedicineWake Forest University School of Medicine306 Westwood Avenue, Suite 401High PointNC27262

ABSTRACT

Objective

To evaluate the epidemiology and outcomes of non-ST-segment-elevation myocardial infarction-cardiogenic shock (NSTEMI-CS) in the United States.

Methods

Adult (>18 years) NSTEMI-CS admissions were identified using the National Inpatient Sample (2000-2017) and classified by tertiles of admission year (2000-2005, 2006-2011 and 2012-2017). Outcomes of interest included temporal trends of prevalence and in-hospital mortality, use of cardiac procedures, in-hospital mortality, hospitalization costs, and length of stay.

Results

In over 7.3 million NSTEMI admissions, CS was noted in 189,155 (2.6%). NSTEMI-CS increased from 1.5% in 2000 to 3.6% in 2017 (adjusted odds ratio 2.03 [95% confidence interval 1.97-2.09]; P < .001). Rates of non-cardiac organ failure and cardiac arrest increased during the study period. Between 2000 and 2017, coronary angiography (43.9%-63.9%), early coronary angiography (13.6%-25.6%), percutaneous coronary intervention (14.8%-31.6%), and coronary artery bypass grafting use (19.0%-25.8%) increased (P < .001). Over the study period, the use of intra-aortic balloon pump remained stable (28.6%-28.8%), and both percutaneous left ventricular assist devices (0%-9.1%) and extra-corporeal membrane oxygenation (0.1%-1.6%) increased (all P < .001). In hospital mortality decreased from 50.2% in 2000 to 32.3% in 2017 (adjusted odds ratio 0.27 [95% confidence interval 0.25-0.29]; P < .001). During the 18-year period, hospital lengths of stay decreased, and hospitalization costs increased.

Conclusions

In the United States, prevalence of CS in NSTEMI has increased 2-fold between 2000 and 2017, while in-hospital mortality has decreased during the study period. Use of coronary angiography and percutaneous coronary intervention increased during the study period.

Il testo completo di questo articolo è disponibile in PDF.

Abbreviations : CABG, CI, CS, ECMO, HCUP, IABP, ICD-9CM, ICD-10CM, MCS, NIS, NSTEMI, OR, PCI, pLVAD


Mappa


 Sources of Funding: Dr. Saraschandra Vallabhajosyula is supported by the Clinical and Translational Science Award (CTSA) Grant Number UL1 TR000135 from the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). Its contents are solely the responsibility of the authors and do not necessarily represent the official view of NIH.
 Disclosures: All authors have reported that they have no relationships relevant to the contents of this paper to disclose.


© 2021  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 244

P. 54-65 - febbraio 2022 Ritorno al numero
Articolo precedente Articolo precedente
  • Electrical cardioversion of atrial fibrillation and the risk of brady-arrhythmic events
  • Peter Vibe Rasmussen, Paul Blanche, Frederik Dalgaard, Gunnar Hilmar Gislason, Christian Torp-Pedersen, Jacob Tønnesen, Martin H. Ruwald, Jannik Langtved Pallisgaard, Morten Lock Hansen
| Articolo seguente Articolo seguente
  • Novel plasma biomarkers predicting biventricular involvement in arrhythmogenic right ventricular cardiomyopathy
  • Deniz Akdis, Liang Chen, Ardan M. Saguner, Ningning Zhang, Joanna Gawinecka, Lanja Saleh, Arnold von Eckardstein, Jie Ren, Christian M. Matter, Zhenliang Hu, Xiao Chen, Felix C. Tanner, Robert Manka, Kai Chen, Corinna Brunckhorst, Jiangping Song, Firat Duru

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.